In recent years, the FDA has approved several new antimicrobials from small companies. Today, nearly every company behind those antibiotics has either gone bankrupt, was acquired for pennies on the dollar, or is under water. After surviving the long, costly road of R&D and securing FDA approval for their treatment, many antimicrobial makers face the “second valley of death” — a broken market that threatens their survival.